<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01752842</url>
  </required_header>
  <id_info>
    <org_study_id>201112122</org_study_id>
    <secondary_id>P20HL113444-01</secondary_id>
    <nct_id>NCT01752842</nct_id>
  </id_info>
  <brief_title>Lipid Biomarkers for Diabetic Heart Disease</brief_title>
  <official_title>Lipid Biomarkers for Diabetic Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leducq Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test whether lowering the delivery of excess fats to the heart in persons
      with type-2 diabetes mellitus improves heart muscle function. The investigators will also
      test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic
      heart disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening procedures include 12-hour fasting blood draw, urine pregnancy testing for females,
      completion of medical history questionnaire, and stress echocardiography to rule out coronary
      artery disease or cardiomyopathy.

      Subjects who meet screening criteria will return for visit 2, which consists of a urine
      collection, 12-hour fasting blood draw, dual-energy X-ray absorptiometry (DXA) for body
      composition, magnetic resonance spectroscopy analysis of the liver, and resting
      echocardiogram for analysis of heart structure and function. Subjects will then be randomized
      to treatment with fenofibrate (160 mg/d) or an identical-appearing placebo for 12 weeks. They
      will be asked to continue their usual medications, diet and physical activity. Subjects will
      receive a pedometer to wear daily to track their physical activity. Subjects will meet with
      dietitians from the Lifestyle Intervention Core to complete a 24-hour dietary recall. They
      will be instructed to record their daily blood glucose concentrations, distance walked and
      any side effects, illnesses or stresses in a study-supplied log. Subjects will be instructed
      to either email or fax the log to the study coordinator each week (or discuss by phone).

      Subjects will return 6 weeks after starting intervention for visit 3 to ensure their medical
      safety. Procedures at this visit include an interim medical history, urine pregnancy test for
      females, blood draw to rule out untoward effects of the study drug on liver or kidney
      function, pill count to assess compliance, review of logs of blood glucose, distance walked,
      and side effects, illnesses or stresses, and meeting with a dietitian for a 24-hour dietary
      recall.

      Subjects will continue to take their study medication/placebo and keep logs of blood glucose
      levels, distance walked, and side effects, illnesses and stresses for another 6 weeks. They
      will return for visit 4 after 12 total weeks of intervention. Visit 4 involves a urine
      collection, 12-hour fasting blood draw, review of subject logs, pill count, and 24-hour
      dietary recall. In addition, magnetic resonance spectroscopy analysis of the liver and
      resting echocardiogram analysis of the heart will be performed to determine if there have
      been any changes in liver fat or heart function during the 12-week intervention.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">February 28, 2019</completion_date>
  <primary_completion_date type="Actual">February 28, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cardiac function as measured by fractional shortening percent</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Type II Diabetes Mellitus</condition>
  <condition>Diabetes Complications</condition>
  <arm_group>
    <arm_group_label>Fenofibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One fenofibrate 160 mg capsule per day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for fenofibrate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One inert sugar pill per day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <arm_group_label>Fenofibrate</arm_group_label>
    <other_name>Tricor</other_name>
    <other_name>Triglide</other_name>
    <other_name>Antara</other_name>
    <other_name>Lipofen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for fenofibrate</intervention_name>
    <arm_group_label>Placebo for fenofibrate</arm_group_label>
    <other_name>Sugar pill manufactured to mimic Fenofibrate 160 mg capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

        Exclusion Criteria:

          -  body weight &gt; 300 lb.

          -  HIV

          -  hypothyroid

          -  steroid medication, fenofibrate

          -  smoking

          -  BP &gt; 140/90

          -  heart disease

          -  pregnant or lactating

          -  consumption of &gt; 5 alcoholic drinks/wk

          -  creatinine &gt; 1.5 mg/dL

          -  hematocrit &lt; 28
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean E Schaffer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974 Jul;34(1):29-34.</citation>
    <PMID>4835750</PMID>
  </reference>
  <reference>
    <citation>Hamby RI, Zoneraich S, Sherman L. Diabetic cardiomyopathy. JAMA. 1974 Sep 23;229(13):1749-54.</citation>
    <PMID>4278055</PMID>
  </reference>
  <reference>
    <citation>Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, Gropler RJ. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation. 2004 May 11;109(18):2191-6. Epub 2004 May 3.</citation>
    <PMID>15123530</PMID>
  </reference>
  <reference>
    <citation>Herrero P, Peterson LR, McGill JB, Matthew S, Lesniak D, Dence C, Gropler RJ. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol. 2006 Feb 7;47(3):598-604. Epub 2006 Jan 18.</citation>
    <PMID>16458143</PMID>
  </reference>
  <reference>
    <citation>Szczepaniak LS, Dobbins RL, Metzger GJ, Sartoni-D'Ambrosia G, Arbique D, Vongpatanasin W, Unger R, Victor RG. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med. 2003 Mar;49(3):417-23.</citation>
    <PMID>12594743</PMID>
  </reference>
  <reference>
    <citation>Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 2004 Nov;18(14):1692-700.</citation>
    <PMID>15522914</PMID>
  </reference>
  <reference>
    <citation>Griffin JA, Osborn BW, Smithline HA. The impact of diabetes on hospital admissions, length of stay and mortality in emergency department patients with acute decompensated heart failure without ischemia. Acad Emerg Med. 2005;12:s97</citation>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2012</study_first_submitted>
  <study_first_submitted_qc>December 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2012</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Diabetic Cardiomyopathy</keyword>
  <keyword>Triglycerides</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

